Biophytis SA filings document its foreign private issuer reporting for an ADR linked to a clinical-stage biotechnology company focused on age-related diseases. The company files Form 6-K reports that furnish press releases, interim financial reporting, meeting results, and other information distributed by the French issuer.
The filing record addresses BIO101 program disclosures, sarcopenia and obesity development updates, strategic and co-development agreements, capital increases, warrants, convertible debt repayment, bond financing amendments, and shareholder governance matters. These disclosures also show how the company reports financing activity and program spending alongside its Euronext Growth Paris ordinary-share listing and OTC ADS program.
Biophytis S.A. submitted a Form 6-K as a foreign private issuer to provide investors with an English-language update about its corporate governance. The company reports that on November 13, 2025 it issued a press release announcing the results of its Combined General Meeting. That press release is included with this report as Exhibit 99.1, allowing shareholders to review the meeting outcomes in more detail.
Biophytis S.A., a foreign private issuer based in Paris, submitted a Form 6-K to provide investors with its Interim Financial Report for the first half of fiscal year 2025. The company states that this interim report, dated October 31, 2025, is attached as Exhibit 99.1 and incorporated by reference, meaning the detailed financial and operational information for the period is contained in that exhibit.
BlackRock Portfolio Management LLC filed a Schedule 13G reporting beneficial ownership of 1,215,469 shares (5.2%) of Biophytis SA common stock. The filing indicates sole voting power over 1,215,469 shares and sole dispositive power over 1,215,469 shares, with no shared voting or dispositive power.
The event date is 09/30/2025. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The CUSIP is F1022R155. Item 6 notes that Kreos Capital VI (Expert Fund) LP has an interest in more than five percent of the company’s common stock.
Biophytis S.A. reported that it issued a press release announcing a partnership with a consortium of investors, including RONGHUI RENHE Life Technology, to finance and launch the first ever Phase-3 trial in sarcopenia. The announcement was furnished on a Form 6-K and the press release is provided as Exhibit 99.1.
Biophytis S.A. filed a Form 6-K to share a press release dated September 15, 2025. The company reports it has secured public funding in Brazil for an obesity phase 2 trial and has signed agreements with leading local clinical partners to conduct this study.